{"preliminary_commentary":{"by_channel":{"x_thread":52,"youtube":31,"podcast":23},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03024996\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"IMmotion 010","nct_id":"NCT03024996","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=immotion-010-nct03024996. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IMmotion010","arms":[{"description":"Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (q3w) for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).","label":"Atezolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo matching to atezolizumab q3w for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2022-12-08","type":"ACTUAL"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":778,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"OTHER"}],"last_update":"2023-08-03","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-05-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Investigator-assessed Disease-Free Survival (DFS)","timeFrame":"From baseline up to first occurence of event by investigator assessment (up to approximately 64 months)"}],"references":[{"citation":"Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10.","pmid":"36099926","type":"DERIVED"},{"citation":"Marconi L, Sun M, Beisland C, Klatte T, Ljungberg B, Stewart GD, Dabestani S, Choueiri TK, Bex A. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. Clin Genitourin Cancer. 2021 Apr;19(2):e92-e99. doi: 10.1016/j.clgc.2020.12.005. Epub 2021 Jan 7.","pmid":"33526329","type":"DERIVED"}],"start_date":{"date":"2017-01-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy","url":"https://clinicaltrials.gov/study/NCT03024996"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/immotion-010-nct03024996"}